ABBV - Embedded Expectations Analysis - 2021 06 15
AbbVie Inc. (ABBV:USA) currently trades below corporate averages relative to UAFRS-based (Uniform) earnings, with a 13.3x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management may have concerns about their Aesthetics franchise, product approvals, and VraylarSpecifically, management may lack confidence in their ability to sustain neuroscience revenue growth, maintain strong top- and bottom-line performance, and cultivate prescription growth across their new immunology agents. Moreover, they may be concerned about Humira biosimilar competition across international markets, the potential of their pivotal program for Skyrizi in Crohn's disease, and the risk-benefit profile of Rinvoq across all indications. Furthermore, management may lack confidence in their ability to drive innovation and investment opportunities in their Aesthetics franchise, obtain commercial approval for new products and indications, including oral CGRP, and launch additional indications for Imbruvica and Venclexta. Additionally, management may lack confidence in their ability to exceed adjusted EPS guidance, gain market share, and further generate expense synergies from their Allergan transaction. Finally, they may be concerned about the pandemic's impact on new patient starts and they may be overstating the potential of Vraylar as a Schizophrenia treatment
AbbVie is a research-based biopharmaceutical company. The company's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions. The company also has medicines in clinical development across immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
- GAAP and IFRS have failed to provide rules for reliable financial statement reporting
- Stock analyst recommendations are not grounded in disciplined financial analysis
- Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
- Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
- Corporate credit ratings remain years behind the fundamental underpinnings of company performance
- Stock analysts continue to make recommendations with deeply inherent biases
- Research firms have failed to break down the walls between credit, equity, and macroeconomic research
- The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.